肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：基质免疫型可以预测肌层浸润膀胱癌患者预后及辅助化疗获益

2018-07-03 MedSci MedSci原创

肌层浸润膀胱癌基质免疫型辅助化疗预后
关注

CLIN CANCER RES近期发表了一篇文章，创建了新的基质免疫型，可以改善肌层浸润膀胱癌（MIBC）患者术后生存及辅助化疗获益预测。

CLIN CANCER RES近期发表了一篇文章，创建了新的基质免疫型，可以改善肌层浸润膀胱癌（MIBC）患者术后生存及辅助化疗获益预测。

研究纳入了上海肿瘤中心118例，中山医院140例以及来自TCGA队列的287例肌层浸润膀胱癌患者。通过免疫组化染色或CIBERSORT评估免疫细胞浸润情况。通过LASSO Cox回归模型在22个免疫指标中选择5个免疫治疗构成免疫型。最终通过LASSO模型，文章将肌层浸润膀胱癌患者分为基质免疫型A（CTL高NK高Treg低巨噬细胞低MC低）和基质免疫型B（CTL低NK低Treg高巨噬细胞高MC高）。免疫型A和免疫型B之间5年总生存率和5年无病生存率差异显着。多因素分析表明，在所有队列中基质免疫型均是独立预后因素。辅助化疗可以显着改善pT3+pT4患者的总生存和无病生存情况。基质免疫型A的免疫检查点分子（PD-L1，PD-1和CTLA-4）表达更高。

文章最后认为，基质免疫型可以有效预测肌层浸润膀胱癌的预后和复发。此外，免疫型可以作为鉴别能从辅助化疗获益的pT3+T4患者的有效工具。

原始出处：

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1757105, encodeId=b60a1e571056e, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Fri Nov 09 19:13:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691987, encodeId=2ec0169198ea6, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Fri Nov 16 19:13:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328997, encodeId=cc9f32899ef2, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Tue Jul 03 15:45:44 CST 2018, time=2018-07-03, status=1, ipAttribution=)]
    2018-11-09 ms7899726347904398

    #基质#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1757105, encodeId=b60a1e571056e, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Fri Nov 09 19:13:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691987, encodeId=2ec0169198ea6, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Fri Nov 16 19:13:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328997, encodeId=cc9f32899ef2, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Tue Jul 03 15:45:44 CST 2018, time=2018-07-03, status=1, ipAttribution=)]
    2018-11-16 bnurmamat

    #患者预后#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1757105, encodeId=b60a1e571056e, content=<a href='/topic/show?id=103b421e0e8' target=_blank style='color:#2F92EE;'>#基质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42170, encryptionId=103b421e0e8, topicName=基质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=281337296540, createdName=ms7899726347904398, createdTime=Fri Nov 09 19:13:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691987, encodeId=2ec0169198ea6, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Fri Nov 16 19:13:00 CST 2018, time=2018-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328997, encodeId=cc9f32899ef2, content=一起学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/TDiaAWyicHgedzX3wKo3qcxudVJib7AfibfvNeufHRF2jG3Bw8MmZyWjIhtBV1mpJI7Sy9n7RcBKK5t3CuOKuOFxkg/0, createdBy=dd702206933, createdName=wzb521zf, createdTime=Tue Jul 03 15:45:44 CST 2018, time=2018-07-03, status=1, ipAttribution=)]
    2018-07-03 wzb521zf

    一起学习学习

    0

相关资讯

JCO：新辅助吉西他滨联合顺铂治疗肌层浸润膀胱癌

新辅助化疗联合根治性膀胱切除是肌层浸润膀胱癌的标准治疗方式。顺铂为基础的剂量密度方案与标志的化疗方案相比有更好的治疗效果，但是理想的新辅助治疗方案仍需进一步探索。JCO近期发表了一篇文章，评估6个周期的新辅助剂量密度吉西他滨联合顺铂（ddGC）治疗肌层浸润膀胱癌患者中的有效性和耐受性。